Feasibility study to assess the delivery of a novel isometric exercise intervention for people with stage 1 hypertension in the NHS: protocol for the IsoFIT-BP study including amendments to mitigate the risk of COVID-19.
COVID-19
Exercise
Feasibility study
General practice
Hypertension
Isometric exercise
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
28 Oct 2021
28 Oct 2021
Historique:
received:
12
01
2021
accepted:
29
09
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Hypertension (HTN) affects approximately 25% of the UK population and is a leading cause of mortality. Associated annual health care costs run into billions. National treatment guidance includes initial lifestyle advice, followed by anti-hypertensive medication if blood pressure (BP) remains high. However, adoption and adherence to recommended exercise guidelines, dietary advice and anti-hypertensive medication is poor. Four short bouts of isometric exercise (IE) performed 3 days per week (d/wk) at home elicits clinically significant reductions in BP in those with normal to high-normal BP. This study will determine the feasibility of delivering personalised IE to patients with stage 1 hypertension for whom lifestyle changes would be recommended before medication within NHS primary care. This is a randomised controlled feasibility study. Participants were 18+ years, with stage 1 hypertension, not on anti-hypertensive medication and without significant medical contraindications. Trial arms will be standard lifestyle advice (control) or isometric wall squat exercise and standard lifestyle advice. Primary outcomes include the feasibility of healthcare professionals to deliver isometric exercise prescriptions in a primary care NHS setting and estimation of the variance of change in systolic BP. Secondary outcomes include accuracy of protocol delivery, execution of and adherence to protocol, recruitment rate, attrition, perception of intervention viability, cost, participant experience and accuracy of home BP. The study will last 18 months. Sample size of 100 participants (50 per arm) allows for 20% attrition and 6.5% incomplete data, based upon 74 (37 each arm) participants (two-sided 95% confidence interval, width of 1.33 and standard deviation of 4) completing 4 weeks. Ethical approval IRAS ID is 274676. Before the efficacy of this novel intervention to treat stage 1 hypertension can be investigated in any large randomised controlled trial, it is necessary to ascertain if it can be delivered and carried out in a NHS primary care setting. Findings could support IE viability as a prophylactic/alternative treatment option. ISRCTN13472393 , registered 18 August 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertension (HTN) affects approximately 25% of the UK population and is a leading cause of mortality. Associated annual health care costs run into billions. National treatment guidance includes initial lifestyle advice, followed by anti-hypertensive medication if blood pressure (BP) remains high. However, adoption and adherence to recommended exercise guidelines, dietary advice and anti-hypertensive medication is poor. Four short bouts of isometric exercise (IE) performed 3 days per week (d/wk) at home elicits clinically significant reductions in BP in those with normal to high-normal BP. This study will determine the feasibility of delivering personalised IE to patients with stage 1 hypertension for whom lifestyle changes would be recommended before medication within NHS primary care.
METHODS
METHODS
This is a randomised controlled feasibility study. Participants were 18+ years, with stage 1 hypertension, not on anti-hypertensive medication and without significant medical contraindications. Trial arms will be standard lifestyle advice (control) or isometric wall squat exercise and standard lifestyle advice. Primary outcomes include the feasibility of healthcare professionals to deliver isometric exercise prescriptions in a primary care NHS setting and estimation of the variance of change in systolic BP. Secondary outcomes include accuracy of protocol delivery, execution of and adherence to protocol, recruitment rate, attrition, perception of intervention viability, cost, participant experience and accuracy of home BP. The study will last 18 months. Sample size of 100 participants (50 per arm) allows for 20% attrition and 6.5% incomplete data, based upon 74 (37 each arm) participants (two-sided 95% confidence interval, width of 1.33 and standard deviation of 4) completing 4 weeks. Ethical approval IRAS ID is 274676.
DISCUSSION
CONCLUSIONS
Before the efficacy of this novel intervention to treat stage 1 hypertension can be investigated in any large randomised controlled trial, it is necessary to ascertain if it can be delivered and carried out in a NHS primary care setting. Findings could support IE viability as a prophylactic/alternative treatment option.
TRIAL REGISTRATION
BACKGROUND
ISRCTN13472393 , registered 18 August 2020.
Identifiants
pubmed: 34711266
doi: 10.1186/s40814-021-00925-w
pii: 10.1186/s40814-021-00925-w
pmc: PMC8551940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
192Informations de copyright
© 2021. The Author(s).
Références
Sports Med. 2000 Jul;30(1):1-15
pubmed: 10907753
BMJ. 2009 May 19;338:b1665
pubmed: 19454737
Clin Hypertens. 2019 Jan 15;25:1
pubmed: 30675379
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Hypertens Res. 2016 Feb;39(2):88-94
pubmed: 26467494
BMJ. 2019 Feb 15;364:l571
pubmed: 30770340
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Hypertens. 2019 Apr;37(4):827-836
pubmed: 30817465
Scand J Med Sci Sports. 2013 Oct;23(5):620-6
pubmed: 22260503
Sci Rep. 2021 Mar 5;11(1):5334
pubmed: 33674722
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Public Health Nutr. 1999 Mar;2(1A):153-60
pubmed: 10933635
Health Psychol Res. 2013 Jan 25;1(1):e6
pubmed: 26973895
Circ Res. 2019 Mar 29;124(7):1124-1140
pubmed: 30920917
Int J Vasc Med. 2012;2012:964697
pubmed: 22991668
Ann Behav Med. 2011 Oct;42(2):197-209
pubmed: 21604068
J Am Heart Assoc. 2013 Feb 01;2(1):e004473
pubmed: 23525435
PLoS One. 2014 Sep 19;9(9):e108019
pubmed: 25237905
J Hum Hypertens. 2010 Dec;24(12):796-800
pubmed: 20182455
Can J Cardiol. 2006 May 15;22(7):553-5
pubmed: 16755308
Health Expect. 2013 Dec;16(4):e89-99
pubmed: 22958162
Eur J Appl Physiol. 2009 Nov;107(5):509-15
pubmed: 19680681
Eur J Appl Physiol. 2021 Jan;121(1):319-329
pubmed: 33070245
Mayo Clin Proc. 2014 Mar;89(3):327-34
pubmed: 24582191
BMJ Open Sport Exerc Med. 2020 Feb 28;6(1):e000672
pubmed: 32180993
BMJ. 2015 Jan 21;350:h100
pubmed: 25608694
Eur J Appl Physiol. 2017 Jan;117(1):83-93
pubmed: 27853886
Arch Intern Med. 2009 Apr 13;169(7):702-7
pubmed: 19365000
J Strength Cond Res. 2014 Jul;28(7):2042-6
pubmed: 24378665
Exp Physiol. 2002 Jul;87(4):507-15
pubmed: 12392115
Eur J Appl Physiol. 2010 Feb;108(3):419-28
pubmed: 19280213
Acta Diabetol. 2005 Apr;42 Suppl 1:S17-25
pubmed: 15868115
Eur J Appl Physiol. 2010 Jul;109(4):601-6
pubmed: 20186425
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
JAMA Intern Med. 2018 Dec 1;178(12):1626-1634
pubmed: 30383082
Int J Obes Relat Metab Disord. 1995 Dec;19(12):893-901
pubmed: 8963358
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
J Sports Sci. 2014;32(2):129-36
pubmed: 23879248
Hypertension. 2018 Jun;71(6):e13-e115
pubmed: 29133356
J Am Soc Hypertens. 2018 Nov;12(11):798-808
pubmed: 30342777
JAMA. 1991 Oct 16;266(15):2098-104
pubmed: 1920698
J Hypertens. 2008 Apr;26(4):819-24
pubmed: 18327094
Sports Med. 2014 Mar;44(3):345-56
pubmed: 24174307
Pilot Feasibility Stud. 2015 Sep 7;1:32
pubmed: 27965810
Eur J Prev Cardiol. 2022 Feb 19;29(1):205-215
pubmed: 33758927
Physiol Rep. 2017 Apr;5(7):
pubmed: 28381447
Prev Med Rep. 2016 Sep 28;4:525-531
pubmed: 27747149
Med Sci Sports Exerc. 2017 Aug;49(8):1511-1519
pubmed: 28708775
Med Sci Sports Exerc. 2004 Mar;36(3):533-53
pubmed: 15076798
Eur J Health Econ. 2015 Jan;16(1):65-72
pubmed: 24390212
Disabil Rehabil. 2015;37(9):795-801
pubmed: 25082472